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Mounting an effective immune response against cancer requires the activation of innate 
and adaptive immune cells. Metastatic melanoma is the most aggressive form of skin 
cancer. While immunotherapies have shown a remarkable success in melanoma treat-
ment, patients develop resistance by mechanisms that include the establishment of an 
immune suppressive tumor microenvironment. Thus, understanding how metastatic 
melanoma cells suppress the immune system is vital to develop effective immunother-
apies against this disease. In this study, we find that macrophages (MOs) and dendritic 
cells (DCs) are suppressed in metastatic melanoma and that the Ig-CDR-based peptide 
C36L1 is able to restore MOs and DCs’ antitumorigenic and immunogenic functions and 
to inhibit metastatic growth in lungs. Specifically, C36L1 treatment is able to repolarize 
M2-like immunosuppressive MOs into M1-like antitumorigenic MOs, and increase the 
number of immunogenic DCs, and activated cytotoxic T cells, while reducing the number 
of regulatory T cells and monocytic myeloid-derived suppressor cells in metastatic lungs. 
Mechanistically, we find that C36L1 directly binds to the MIF receptor CD74 which is 
expressed on MOs and DCs, disturbing CD74 structural dynamics and inhibiting MIF 
signaling on these cells. Interfering with MIF–CD74 signaling on MOs and DCs leads to 
a decrease in the expression of immunosuppressive factors from MOs and an increase 
in the capacity of DCs to activate cytotoxic T cells. Our findings suggest that interfering 
with MIF–CD74 immunosuppressive signaling in MOs and DCs, using peptide-based 
immunotherapy can restore the antitumor immune response in metastatic melanoma. 
Our study provides the rationale for further development of peptide-based therapies to 
restore the antitumor immune response in metastatic melanoma.
Keywords: metastatic melanoma, macrophages, dendritic cells, immune response, peptide-based immunotherapy, 
macrophage migration inhibitory factor, cD74
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inTrODUcTiOn
Cutaneous melanoma is a cancer that develops from melano-
cytes generally located in the epidermal basal cell layer of the 
skin. At  very-early stages, single skin lesions can be promptly 
excised and the 5-year survival rate of melanoma is 98%. Beyond 
these stages, however, melanoma can metastasize to distant 
organs including lungs, liver, bones, and brain, and the 5-year 
survival rate in stage IV drastically decreases to 15–20% (1, 2). 
The aggressiveness of melanoma is associated with a strong bur-
den of somatic mutations (3), with different neoepitopes making 
melanoma cells immunogenic and boosting the immune response 
(4, 5). To evade the immune response, melanomas often activate 
negative immune checkpoint regulators (ICRs) such as PD-1 and 
PD-L1 or CTLA-4 that inhibit effector T  cell and function in 
peripheral tissues or lymph nodes, respectively (6, 7). Inhibition 
of the ICRs with anti-PD-1 and anti-CTLA-4 antibodies enables 
T-cell-mediated killing of melanoma cells and significantly 
improved patient outcomes in recent years (5). However, immune 
checkpoint inhibitors (ICI) are only effective if effector T  cells 
infiltrate the tumor. The generation of effector T  cells requires 
the activation and function of antigen-presenting cells (APCs), 
such as dendritic cells (DCs) and macrophages (MOs) (8, 9). 
DCs and MOs are cells from the innate immune system that are 
essential for starting and shaping the immune response against 
any damaged tissue, including cancer (7, 10).
Tumor-associated macrophages (TAMs) are one of the most 
predominant immune cells in melanomas, and the number of 
TAMs inversely correlates with patients’ outcome, in both early 
and late stages of melanoma (11). MOs can be polarized into 
M1-like antitumorigenic and M2-like immunosuppressive MOs 
(12). We and others have shown that, in tumors, MOs are often 
polarized into M2-like MOs that support tumor cell prolifera-
tion, survival, metastasis, resistance to therapy, and suppress the 
antitumor immune response (12–16). Similarly, DCs can also 
acquire immunogenic or tolerogenic behaviors depending on 
their maturation status (17). Immunogenic DCs support T cell 
activation and function (17, 18). However, immunogenic DCs 
often switch into a tolerogenic phenotype during cancer pro-
gression, which inhibits the activation and function of effector 
T cells (19, 20). Tumor cells contribute to the establishment of 
an immunosuppressive environment by secreting factors that 
polarize MOs into M2-like immunosuppressive MOs and sup-
press DCs immunogenic functions leading to Ref. (7, 16, 21). 
Thus, understanding how metastatic melanoma suppresses the 
immune system is vital for the development of therapies that 
restore an effective antitumor immune response.
Bioactive peptides based on immunoglobulin complemen-
tary determining regions (CDRs) are promising candidates for 
adjuvant cancer therapy and can stimulate the innate immune 
system (22–24). We have previously shown that different CDR 
peptides display antitumor activities against melanoma and are 
able to regulate receptors and transcription factors on both tumor 
cells and immune cells (24–28). Recently, we identified the C36 
VL CDR1 peptide (C36L1) as an antitumor CDR-based peptide 
that inhibits metastatic melanoma cells proliferation and growth 
in vitro and in vivo (24, 25). However, the mechanism by which 
C36L1 inhibits metastatic melanoma progression in a syngeneic 
model remains unknown.
In this study, we found that C36L1 inhibits metastatic 
melanoma only in mice that have a competent immune system. 
C36L1 supports M1-like antitumorigenic MOs and restores DCs 
pro-inflammatory phenotype and immunogenic function. C36L1 
activation of MOs and DCs results in a significant increase in the 
infiltration of effector T cells in the metastatic lungs, leading to a 
marked decrease in the tumor burden.
Macrophage migration inhibitory factor (MIF) is an inflamma-
tory cytokine and an important regulator of the innate immune 
system. Previous studies have shown that MIF can induce an 
immunosuppressive environment that supports melanoma pro-
gression (29, 30). However, the mechanisms by which MIF sup-
presses the immune cells remain poorly understood. CD74 is the 
main receptor for MIF. CD74 is the invariant chain of the MHC 
class II and plays an important role in antigen presentation. CD74 
is highly expressed in APCs such as MOs and DCs (31, 32). Thus, 
MIF and CD74 are emerging attractive targets for immunotherapy.
In this study, we show that the C36L1 peptide binds to CD74 
in both MOs and DCs, disturbing its structural dynamics and 
inhibiting the MIF–CD74 signaling and the immunosuppressive 
effect on MOs and DCs. These findings highlight the MIF–CD74 
axis as an important mechanism of MO and DC immunosup-
pression in metastatic melanoma, and provide a rationale for 
further evaluation of CDR-based peptides as therapeutic agents 
able to restore MOs and DCs’ antitumor functions in metastatic 
melanoma.
MaTerials anD MeThODs
cell culture
Murine melanoma B16F10 cells were cultured in complete 
RPMI-1640 medium (Thermo Fisher, Waltham, MA, USA) sup-
plemented with 10 mM N-2-hydroxyethylpiperazine-N2-ethane 
sulfonic acid (HEPES), 24  mM sodium bicarbonate, 40  mg/L 
gentamicin, pH 7.2, and 10% fetal bovine serum (FBS), at 37°C. 
Primary MOs and myeloid DCs were generated from C57BL/6 
mice bone marrows and cultured in complete Dulbecco’s Modified 
Eagle Medium (DMEM) (Thermo Fisher) supplemented with 
M-CSF1 (10  ng/mL) and RPMI-1640 medium supplemented 
with GM-CSF (50  ng/mL) and IL-4 (25  ng/mL), respectively. 
Cultures were regularly checked for contamination.
Mice and In Vivo Metastatic Melanoma 
studies
6- to 8-Week-old healthy male C57BL/6 [wild type (WT)] or 
NOD/Scid/IL-2rγnull (NSG) mice (n = 5, per group) were intra-
venously challenged with 5 × 105 (for WT) or 5 × 104 (for NSG) 
syngeneic B16F10 viable cells in 0.1 mL of RPMI medium without 
FBS, and treated on the next day with intraperitoneal doses of 
300 µg (10 mg/kg) of C36L1 peptide, for five consecutive days, or 
with control vehicle (PBS). After 14 days, mice were euthanized, 
and lungs were harvested and assessed for metastatic coloniza-
tion. The number of metastatic lesions was quantified using a 
stereo microscope (magnification, 4×) (Nikon, Tokyo).
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Peptides
Peptides were purchased from Peptide 2.0 (Chantilly, VA, 
USA). C36L1 peptide (KSSQSVFYSSNNKNYLA-NH2) and the 
irrelevant iCDR control peptide (CE48-H2, INSGGGGTYYADS 
VKG-NH2) were synthesized with an amide group in the 
C-terminus, at 95–98% purity, determined by high-performance 
liquid chromatography using a C18 column and subsequently 
analyzed by mass spectrometry.
Tissue Paraffin immunofluorescence
Deparaffinization and antigen retrieval were performed in 
mouse melanoma lung metastasis using a PT-link system 
(Dako) and stained as previously described (13) The following 
antibodies were used for immune stainings: anti-iNOS, anti-
CD206, anti-CD103, anti-Ki67, anti-granzyme B, anti-MPO, 
anti-CD86, anti-CD68, anti-MHC-II, anti-CD11b, anti-Ly6C, 
anti-Ly6G, and anti-PD-L1 all purchased from Abcam; anti-
CD11c and anti-F4/80, purchased from BioLegend; anti-Foxp3 
(Cell Signaling); anti-Arg1 (Bioss) and anti-CD8 (Dako) 
primary antibodies, anti-CD4 (BioLegend) and anti-CD25 
(R&D Systems) followed by fluorescently labeled secondary 
antibodies. Images were acquired using an Axio Observer Light 
Microscope with the Apotome.2 (Zeiss). Metastatic melanoma 
lesions were gated by generating a region of interest (ROI), and 
threshold merge fluorescence was limited to ROI and calcu-
lated using the NIS-Elements Advanced Research 4.0 software 
(Nikon, Tokyo).
Flow cytometry analysis
Lungs from C36L1-treated and control mice were digested in 
 collagenase A and purified for CD11c+ DCs using a magnetic 
bead affinity chromatography approach (Miltenyi Biotec, Woking, 
UK). Both enriched CD11c+ and CD11c− cell fractions were used 
for DCs and lymphocyte analysis, respectively. DCs were stained 
with  anti-CD11c (V450), anti-CD86 (PE-Cy7), anti-MHC-II 
(V500), and anti-CD197 (PERCP-CY5.5). Tumor-infiltrating 
lymphocytes were characterized using anti-CD3 (PE), anti-CD4 
(FITC), anti-CD8 (FITC), and anti-NK1.1 (FITC). To analyze 
splenic Treg cells and MOs, fresh spleens were obtained from 
mice after treatments and probed with the following conjugated 
antibodies: anti-CD4 (FITC) and anti-Foxp3 (APC) for lym-
phocyte analysis, anti-F4/80 (FITC), anti-CD86 (PE-Cy7), and 
anti-CD40 (APC) for MO analysis. All antibodies were purchased 
from BD Pharmingen (Franklin Lakes, NJ, USA). Samples were 
analyzed by flow cytometry using a FACSCanto II (Becton 
Dickinson, San Jose, CA, USA). Acquired data were analyzed 
using the FlowJo V10 software (TreeStar Inc., Ashland, OR, USA).
TgF-β elisa assay
CD11c+ DCs (1 × 105) were purified from lymphoid tissues of 
C36L1-treated mice and control vehicle (PBS) using the mouse 
Pan Dendritic Cell Isolation Kit according to manufacturer’s 
instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Primary myeloid DCs were cultured for 48  h at 37°C, and the 
supernatant was collected for TGF-β quantification using the 
mouse-TGF-beta ELISA Set (BD, OptEIA™) detection kit 
according to the manufacturer’s instruction.
Tumor-conditioned Medium (TcM) 
Preparation
B16F10 melanoma cells were cultured in 175 cm2 culture flasks 
and in complete RPMI-1640. When cells reached 70% of conflu-
ence, the medium was harvested, filtered for functional assays 
or concentrated using StrataClean Resin (Agilent Technologies) 
for MIF detection by immunoblot. Alternatively, to increase 
the concentration of tumor-secreted factors, B16F10 cells were 
subcultured in TCM and fresh media (v/v).
generation of Bone Marrow-Derived MOs 
and Myeloid Dcs
Bone marrow cells were isolated from the femurs of C57BL/6 mice 
in cold MAC buffer (Ca2+, Mg2+ free PBS + 2 mM EDTA + 0.5% 
BSA), centrifuged at 1,200 rpm for 10 min, resuspended in 5 mL 
RBC Lysis Buffer (1×, BD Pharm Lyse) and incubated for 5 min 
at RT. Reaction was terminated in PBS, and cells were centrifuged 
at 1,200 rpm for 10 min at RT. Cells were resuspended in 5 mL of 
MAC buffer and carefully added in the top of 5 mL of Histopaque 
solution (Sigma-Aldrich) in 15  mL tubes and centrifuged at 
1,200 rpm, 25 min at 15°C without brake and one acceleration. 
The monocyte-enriched fraction was collected in a new tube and 
washed in PBS. Monocytes were further incubated with M-CSF-1 
(10 ng/mL) in complete DMEM media (Thermo Fisher) to gen-
erate MOs (13), or GM-CSF (50 ng/mL) plus IL-4 (25 ng/mL) 
in complete RPMI to generate myeloid DCs (17, 33). To gener-
ate macrophage-conditioned media (MCM) for the experiment 
described in Figure  6, MOs were incubated with TCM, MIF 
(200  ng/mL) or left untreated, in the presence or absence of 
C36L1  peptide (200  µM) for 72  h, and further incubated in 
serum-free medium for 48 h. Then, the medium was harvested, 
centrifuged, and filtered for functional assays or stored at −20°C.
cD8+ T cells isolation From naïve 
splenocytes
Lymphocytes were obtained from fresh spleens of naïve mice. 
The  negative CD8a+ T Cell Isolation Kit (Miltenyi Biotec, 
Woking, UK) was used to purify CD8+ naïve lymphocytes as per 
manufacturer’s instructions.
Flow cytometry analysis of Primary Dcs
For flow cytometry analysis of primary myeloid DCs, cells were 
harvested from cultures and blocked with PBS/BSA 1% plus 
TruStain fcX anti-mouse CD16/32 (BioLegend) and stained using 
the following conjugated antibodies: DCs: anti-CD11c (APC), 
anti-CD11b (FITC), anti-MHC-II (Percp-Cy5.5), anti-CD80 
(PE-Cy7), and anti-CD86 (PE), all purchased from BioLegend. 
Stained cells were acquired using Attune™ NxT Acoustic Focusing 
Cytometer (Thermo Fisher). Data analysis was performed using 
FlowJo software (Tree Star, Ashland, OR, USA).
immunofluorescence and confocal 
Microscopy
Fluorescence microscopy of B16F10 cells was performed using 
the following antibodies: rabbit anti-MIF antibody (Abcam) and 
secondary antibody solution (anti-rabbit IgG Alexa Fluor 488 
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(Abcam) and 10 µg/mL of Hoechst 33342). Confocal microscopy 
for detection of CD74 interaction with C36L1 was performed 
using a biotinylated C36L1. Briefly, tumor cells were incubated 
with C36L1 (300  µM) and stained using primary mouse- 
anti-CD74 (Abcam) and a secondary anti-mouse IgG Alexa 
Fluor 488 (Abcam) (Green) and Hoechst 33342 (Blue) (Sigma-
Aldrich). Streptavidin-Alexa Fluor 594 (red) (Life Technology) 
was used to probe biotinylated C36L1. Fluorescence and confocal 
Imaging was performed using an Axio Observer Fluorescence 
Microscope with the Apotome.2 (Zeiss) and a confocal Zeiss 
LSM 780 microscope with the 63× 1.4 NA objective, respectively. 
Colocalization analysis was performed using ImageJ software.
Primary MOs and Myeloid Dcs culture 
assays
Primary MOs and myeloid DCs were generated as described 
 earlier. 5 × 105 cells were seeded in 12-well plates in complete fresh 
media, and 200 µM of C36L1 peptide was added to the cultures 
for at least 6 h before the addition of B16F10 TCM or 200 ng/mL 
of recombinant MIF (R&D System, Minneapolis, MN, USA). 
Cells were incubated at 37°C for 72 h and further used in FACs 
analysis for phenotyping or functional assays.
Dc stimulation for cD8+ T cell activation 
assays
Primary myeloid DCs incubated with C36L1 (200 µM) peptide 
for 6 h before incubation with recombinant MIF at 200 ng/mL 
for 72 h. Cells were treated with 200 μM of the tyrosinase-related 
protein 1 peptide (NDPIFVLLH) as an MHC class I related mela-
noma antigen. CD8+ T cells previously incubated with 30 U/mL 
of IL-2 and anti-CD3/CD28 dynabeads (Thermo Fisher) were 
cocultured for 5  days with myeloid DCs in the presence of 
30 U/mL of IL-12 (PeproTech, London, UK). CD8+ T cells were 
harvested and cocultured with B16F10 melanoma cells (10:1) for 
72 h. CD8+ T cells were removed from cultures, and remaining 
viable B16F10 cells were quantified with a Neubauer chamber 
using the Trypan Blue dead cells exclusion stain and the MTT 
colorimetric based assay.
B16F10 Proliferation assay With McM
To obtain different MCM, primary MOs were cultured in the fol-
lowing conditions for 72 h: (1) alone, (2) in the presence of TCM 
or with recombinant MIF (200  ng/mL), and (3) pre-incubated 
for 6 h with C36L1 peptide (200 µM) followed by TCM or MIF 
(200  ng/mL) incubation. Next, the medium was removed, and 
MOs were further cultured with serum-free medium for 48  h 
to produce MCM corresponding to the different conditions 
(MCM1, MCM2, and MCM3). MCM was harvested from the 
different MO culture conditions, filtered through 0.45  µm and 
added to 2 × 103 B16F10 melanoma cells plated in 96-well plates 
stained with CFSE (Thermo Fisher). B16F10 melanoma cells 
were cultured with the different MCMs for 72 h. Next, B16F10 
cells were harvested from wells, stained with propidium iodide 
(10 µg/mL), and the total number of viable (PI−) and proliferating 
cells (CFSE−) was quantified by flow cytometry acquiring fixed 
volumes of cell suspension using an Attune Flow Cytometer.
Quantitative real-Time Pcr (qPcr) 
experiments
Total RNA from primary MOs previously stimulated with C36L1 
(200  µM) for 6  h and TCMs from B16F10 melanoma cells or 
recombinant MIF (200 ng/mL) for 72 h was isolated using the 
RNeasy® Mini Kit (Qiagen, Hilden, Germany). cDNA was pre-
pared from 100 ng RNA per sample, and qPCR was performed 
using gene-specific QuantiTect Assay primers (Qiagen) following 
the manufacturer’s instructions. qPCR reactions were performed 
using FIREPol® EvaGreen® qPCR Mix Plus ROX (Solis Biodyne, 
Tartu, Estonia) in a MaxQuant system. The following primers 
were used: TGF-β (Mm_Tgfb1_1_SG, Qiagen), IL-10 (Mm_ 
IL10_1_SG, Qiagen), PD-L1 (Mm_Pdcd1Ig1 _1_SG, Qiagen), 
Arginase-1 (Mm_ Arg1_1_SG, Qiagen), IL-6 (Mm_Il6_1_SG, 
Qiagen), and GAPDH (Mm_Gapdh_3_SG, Qiagen). Relative 
expression levels were normalized to Gapdh expression accord-
ing to the formula < 2
− −( )C Ctgene of interest tgapdh  (13) and displayed as fold 
change units.
Protein extraction and immunoblotting
Primary MOs and myeloid DCs were serum starved for 24  h, 
treated with C36L1 (200  µM) for 6  h (or left untreated) and 
stimulated with recombinant MIF (200 ng/mL) at different time 
points for determination of AKT and ERK1/2 phosphorylation. 
Protein lysates were separated by electrophoresis, and immuno-
blotting analyses were performed for: total AKT, total p44/42 
MAPK (ERK1/2), phospho-AKT (Ser473), and phospho-ERK1/2 
(Thr202/Tyr204). HRP-conjugated secondary antibodies were 
used, followed by incubation with the ECL substrate (Pierce). 
All primary and secondary antibodies were purchased from 
Cell Signaling Technologies (Beverly, MA, USA). Anti-GAPDH 
(Sigma) was used as protein loading control. To assess the pres-
ence of MIF in the TCM, TCM was filtered with 0.45-µm filter and 
concentrated using StrataClean Resin (Agilent Technologies), 
and immunoblotted for MIF (Abcam). Phosphorylation ratios 
were quantified using ImageJ gels’ algorithm, normalized to 
untreated control lanes.
Peptide/Protein Binding Prediction
The computational modeling platform PepSite 2.0 (Russel-Lab) 
(34) was used to predict the binding probability of peptides to 
mouse MIF (PDB: 1MFI, chain B) and mouse CD74 (PDB: 1IIE, 
chain B) proteins. Results are displayed as p values, where p ≤ 0.05 
values are the statistically significant binding predictions. iCDR 
peptide was used as a negative peptide control. Binding prob-
ability was calculated using the interval 0.01 < p < 0.05, where 
p =  0.01 represents 100% of binding probability and p >  0.05 
represents 0% of binding probability.
c36l1 Preparation and Molecular 
Dynamics (MD)
We obtained the 3D structure of C36L1 by performing de 
novo structure prediction in Pep-Fold3 web server. To per-
form molecular docking experiments, we carried out an MD 
simulation on GROMACS 5.1 using CHARMM36 force field. 
We set up the simulation system on CHARMM-GUI web server. 
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We clustered the MD trajectory to obtain a diverse conformational 
population to perform molecular docking. All MD frames fitted 
the reference structure and clustered with GROMOS method 
by using GROMACS 5.1, with a backbone root-mean-squared 
deviation cutoff of 5.0 Å for C36L1, resulting in eight different 
clusters. The center structure of each cluster was used in docking 
simulations.
cD74 normal Mode calculations and 
generation of low-energy conformations
The CD74 structure 1IIE (35) (residues from 118 to 176) was 
used to perform normal modes analysis using CHARMM c41b1 
and CHARMM36 force filed using DIMB module. A distance-
dependent dielectric constant was employed to treat the electro-
static shielding from solvation. The five lowest-frequency normal 
modes were computed as directional constraint to generate low-
energy conformers along the mode trajectory using the VMOD 
algorithm in CHARMM, as previously described (36, 37). 
The restraints were applied only on Cα atoms, and the energy 
was computed for all atoms. The structures were displaced from 
−3.0 Å to +3.0 Å using steps of 0.1 Å, resulting in 61 intermediate 
energy relaxed structures along each mode.
Molecular Docking
Molecular docking simulations were performed using iATTRACT 
algorithm depicting conformational selection and induced fit 
between both partners. Various conformations of both receptor 
and ligand (ensemble docking) were simultaneously combined 
among interface flexibility and rigid body optimizations during 
docking energy minimization. The best 50 solutions were written 
for each combination. BINANA 1.2 was used to investigate the 
specific molecular basis guiding the interaction between CD74 
and C36L1.
chemiluminescent Dot-Blot Binding assay
Interaction between the peptide C36L1 and recombinant CD74 
was determined by chemiluminescent dot blotting carried out 
as previously described (24). Briefly, 25 nmol of C36L1 and the 
 irrelevant CDR peptide control (iCDR) and vehicle (0.025% 
DMSO in dH2O) were immobilized on nitrocellulose membranes, 
blocked and incubated with 25 nM of recombinant CD74 (Abcam) 
overnight at 4°C. Membranes were washed and incubated with 
primary mouse anti-CD74 (Abcam), washed and incubated with 
secondary anti-mouse IgG-HRP (CST). Immunoreactivity was 
determined using the ECL Western Blotting Substrate (Pierce™), 
and signal was detected in a transilluminator Alliance 9.7 (Uvitec, 
Cambridge, UK).
statistics
All statistic tests were performed using the GraphPad Prism 5.0 
software (San Diego, CA, USA). Statistical differences between 
experimental and control group were calculated using the 
Student’s t-test. In vitro experiments were performed in tripli-
cates. In vivo experiment was performed with at least n = 5 per 
treatment group. Sample size for each experiment is described in 
figure legends. Significant differences are indicated by *p < 0.05, 
**p < 0.01, and ***p < 0.001.
resUlTs
The antimetastatic effect of the c36l1 
Peptide requires the immune system
We have previously shown that intraperitoneal injections of the 
antitumor CDR peptide C36L1 significantly decrease pulmonary 
melanoma metastasis in a syngeneic model (24, 25). In addition, 
bone marrow-derived myeloid pro-inflammatory DCs displayed 
equivalent antitumor effect when tumor antigen-primed DCs 
were pretreated with C36L1 ex vivo and adoptively transferred to 
mice bearing lung melanoma metastasis (24). These findings sug-
gest that the antitumor effects induced by C36L1 in vivo may result 
from the peptide ability to stimulate the host immune response. To 
further investigate the mechanism of action of C36L1, we treated 
immunocompetent C57BL/6 and immunodeficient NOD/Scid/
IL-2rγnull mice bearing melanoma lung metastasis with C36L1 
peptide or control vehicle (Figure 1A). We observed that C36L1 
significantly decreased lung metastasis in immunocompetent 
mice but not in immunodeficient mice (Figure 1B). These find-
ings confirm that C36L1 antitumor effect is driven by its ability 
to stimulate the immune response against metastatic melanoma.
c36l1 restores MOs and Dcs 
immunogenic Functions in Metastatic 
Melanoma
Macrophages and DCs are vital for activating effector T cells and 
shaping the immune response against cancer (7). In solid tumors, 
including melanomas, MOs and DCs are suppressed by the tumor 
and lose their ability to activate and support the immune response 
against cancer (12, 17). TAMs often acquire an M2-like pheno-
type that hampers the antitumor immune response and supports 
tumor growth, metastasis, and resistance to therapies (12–14, 38). 
Similarly, intratumoral DCs often acquire a tolerogenic pheno-
type and lose their ability to activate effector T cells (17, 39, 40). 
Thus, effective anticancer immunotherapies must reverse the 
tumor immunosuppressive environment and restore the immu-
nogenic functions of MOs and DCs. In this respect, we found 
that C36L1 is able to repolarize M2-like (F4/80+CD206+Arg1+) 
TAMs into M1-like (F4/80+iNOS+CD86+MHC-II+) pro-
inflammatory and antitumorigenic MOs (Figure  1C; Figures 
S1A–C in Supplementary Material). In addition, increased levels 
of M1-like MOs were also observed in the spleens of C36L1-
treated mice, compared with control-treated mice (Figure S5A in 
Supplementary Material). The number of activated intratumoral 
DCs (CD11c+, MHC-II+, CD197+, CD40+, CD86+, and CD103+) 
in metastatic lungs from C36L1-treated mice was significantly 
increased compared with control-treated mice (Figure 1D; Figure 
S1D in Supplementary Material). The number of neutrophils and 
polymorphonuclear myeloid-derived suppressor cells did not sig-
nificantly change between control- and C36L1-treated metastatic 
lungs (Figures S3A,B in Supplementary Material). However, we 
observed a small but statistically significant decrease in the num-
ber of monocytic myeloid-derived suppressor cells (Figure S3C 
in Supplementary Material). C36L1 treatment decreased the 
secretion of the immunosuppressive cytokine TGF-β by CD11c+ 
DCs from lymphoid organs (spleens and cervical lymph nodes) 
FigUre 1 | The antimetastatic effect of the C36L1 peptide depends on the immune system. (a) Metastatic melanoma model and therapeutic strategy using C36L1 
peptide and control vehicle (PBS). At end point, lungs, cervical lymph nodes, and spleens are harvested. (B) Number of metastatic foci in immunocompetent (wild 
type) and immunodeficient (NOD/Scid/IL-2rγnull, NSG) mice treated with control vehicle (PBS) or C36L1 peptide. n = 10 mice per group (two combined experiments). 
Values are expressed as means ± SEM and were analyzed using a two-tailed unpaired t-test (**p = 0.001). Graph combines two independent experiments. (c) Left: 
Immunofluorescent staining and quantification of F4/80+Arg.1+ M2-like and F4/80+iNOS+ M1-like macrophages in lung metastasis from C36L1- and control 
vehicle-treated mice. Melanoma lung metastatic area appears in dark/brown color in brightfield images. Right; Graphs show quantification of positive F4/80+Arg1+ 
(*p = 0.028) and F4/80+iNOS+ (*p = 0.02) stainings. Nuclei were counterstained with Hoechst 33342 (blue). N = 5 mice per group; at least five fields assessed per 
sample. Values are expressed as means ± SEM and were analyzed using a two-tailed unpaired t-test. Blue and red lines indicate the tumor area in C36L1- and 
control vehicle-treated mice, respectively. Scale bars: 50 µm. (D) Flow cytometry quantification of activation markers MHC-II (**p = 0.003), CD197 (**p = 0.002), 
CD86 (*p = 0.019), and CD40 (**p = 0.007) expressed in CD11c+ dendritic cells (DCs) isolated from lungs of C36L1- and control vehicle-treated mice. Data 
represent quantification of four independent experiments with five pooled lungs per group for each experiment. Values are expressed as means ± SEM and were 
analyzed using a two-tailed, unpaired t-test. (e) Quantification of CD4+ (*p = 0.03), CD8+ (**p = 0.005), and NK1.1+ (*p = 0.02) cells among CD3+ cells in lung 
metastatic lesions from C36L1- and control vehicle-treated mice. Bar graphs combine three independent in vivo experiments with five pooled lungs per group for 
each experiment. Values represent means ± SEM and were analyzed using a two-tailed unpaired t-test.
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FigUre 2 | C36L1 counteracts the pro-tumorigenic activity of macrophages (MOs) induced by melanoma derived factors. Left: Schematics describing the workflow 
of the tumor cell proliferation assay. Tumor cells are exposed to either conditioned media from: untreated MOs (MCM1), MOs exposed to tumor-conditioned media 
(TCMs) from metastatic melanoma B16F10 cells (MCM2), or MOs exposed to C36L1 peptide + TCM from B16F10 cells (MCM3). Next, macrophage conditioned 
media (MCM) generated from these three conditions were added into B16F10 melanoma, cells and the number of live proliferating cells was quantified by flow 
cytometry after 72 h. Right: Bar graph represents average of three independent experiments (n = 3). Values represent means ± SEM, and data were analyzed using 
a two-tailed unpaired t-test (***p < 0.001).
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(Figure S5B in Supplementary Material). These findings suggest 
that C36L1 repolarizes and reactivates MOs and DCs’ immuno-
genic and antitumorigenic functions in metastatic melanoma.
c36l1 increases the level of effector  
T cells in the TMe
Tumor-specific antigen presentation by DCs and MOs to effector 
T cells is a crucial step for the generation of an effective immune 
response against cancer, and increased infiltration of effector 
T cells in tumors is a good prognostic marker (4, 5). Since treat-
ment with C36L1 decreases melanoma pulmonary metastasis 
and increases the numbers of pro-inflammatory MOs and DCs, 
we asked whether C36L1 increases effector T cell infiltration in 
metastatic tumors. We found that, indeed, C36L1 significantly 
increased the levels of CD4+ T cells from 6.86 to 13.35%, CD8+ 
cytotoxic T cells from 6.11 to 17.6%, and NK1.1+ natural killer 
(NK) cells from 8.44 to 16.13%, in lung metastatic melanoma 
(Figure 1E; Figure S6A in Supplementary Material). CD8+ cyto-
toxic T cells number and proliferative (CD8+Ki67+) and activation 
status (CD8+GranzymeB+) were significantly increased in C36L1 
treated metastatic lungs compared with control-treated lungs 
(Figures S2A,B in Supplementary Material). We also observed a 
decrease in the number of regulatory T cells (CD4+CD25+FoxP3+) 
in metastatic lungs from C36L1-treated mice compared with 
control mice (Figures S2C,D in Supplementary Material). In 
lymphoid organs, tolerogenic DCs are responsible for inducing 
Foxp3+ Tregs differentiation by secreting TGF-β. Since C36L1 
treatment decreases TGF-β production by DCs (Figure S5B in 
Supplementary Material), we evaluated whether Tregs were 
also reduced in lymphoid organs upon C36L1 treatment. Flow 
 cytometry analysis of mice splenocytes revealed a highly signifi-
cant decrease in the percentage of CD4+Foxp3+ Tregs from 59.6 to 
1.39% following C36L1 treatment (Figure S6B in Supplementary 
Material). Together, these findings indicate that C36L1 restores 
DCs and MOs immunogenic functions, increases effector T cell 
infiltration in metastatic tumors, and inhibits immunosuppres-
sive regulatory T cells.
c36l1 inhibits the suppressive effects  
of Tumor-secreted Factors in MOs
Tumor educated MOs exhibit an M2-like phenotype and support 
cancer progression in several ways, including the direct support 
of  cancer cell proliferation (17). To further understand how 
C36L1 affects MO function, we cultured metastatic B16F10 mela-
noma cells with conditioned media from tumor educated MOs 
(MOs previously exposed to TCMs) in the presence or absence of 
C36L1. As expected, melanoma cells exposed to tumor educated 
MOs showed a significant increase in proliferation. Addition 
of C36L1 abrogated this MO-driven tumor cell proliferation 
(Figure 2; Figure S6C in Supplementary Material). These results 
show that MOs exposed to TCMs acquire pro-tumorigenic func-
tions, and this can be inhibited by C36L1 peptide. These findings 
suggest that C36L1 must interfere with a tumor secreted factor 
(or its receptor) that regulates MO function.
c36l1 Binds to MiF receptor, cD74
C36L1 is a linear and flexible CDR-based peptide. Linear peptides 
are likely to adopt a few stable conformations and interactive 
possibilities to different relevant targets (41). Previous studies 
have shown that stromal and melanoma cells express high levels 
of MIF, supporting melanoma growth and modulating immune 
cells in late-stage melanoma (29, 30, 42–46). DCs and MOs both 
express MIF’s main receptor, CD74 (47). Thus, we hypothesize 
that C36L1 could interfere with MIF signaling on MOs and DCs. 
In agreement with previous studies, we observed that B16F10 
metastatic melanoma cells express and secrete high levels of MIF 
in vitro (Figures 3A,B), and that MIF is highly expressed in small 
and large lung metastatic melanoma lesions (Figure 3C).
FigUre 3 | Macrophage migration inhibitory factor (MIF) is secreted by B16F10 metastatic melanoma cells and is highly expressed in lung metastatic lesions.  
(a) Immunofluorescent staining of B16F10 cells stained for MIF (green) and nuclei (blue). Scale bars: 50 µm. (B) Immunoblotting analysis of B16F10 tumor-
conditioned media (TCMs) detecting secreted MIF. (c) Immunohistochemical staining of lung melanoma metastasis showing MIF (in red) in small and large 
lesions. Dark brown areas are metastatic foci of melanoma cells. Scale bars: 200 µm (left) and 50 µm (right).
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A pilot study addressing the binding probability of C36L1 to 
MIF and its receptor CD74 was carried out using the compu-
tational modeling prediction of peptide-binding sites to protein 
surfaces and the PepSite 2.0 algorithm (34). This in silico approach 
predicted a statistically significant binding of C36L1 to mouse 
CD74 B chain (PDB: 1IIE) protein (p < 0.001), and a potential 
binding to mouse MIF B chain (PDB: 1MFI) protein (p = 0.04) 
(Figure 4A). No interaction with either CD74 or MIF was pre-
dicted for an irrelevant control CDR peptide (iCDR—CE48-H2), 
which was previously observed to have no effect on metastatic 
melanoma proliferation in  vitro and progression in  vivo (25) 
(Figure 4A; Figure S7A in Supplementary Material). We used the 
PepSite 2.0 algorithm to identify the amino acid residues involved 
in the interaction of C36L1 to CD74 and found that the peptide 
is predicted to interact with Tyr (118), Arg (179), and His (180) 
residues from the B chain of the murine/human CD74 protein, 
highlighted in red (Figure S7B in Supplementary Material). 
Interestingly, Meza-Romero et  al. have recently described that 
some of these residues (highlighted in green) are also critical for 
the interaction of MIF with the CD74 antagonist (RTL-1000) 
(48). The in silico predicted interaction of C36L1 with CD74 was 
further confirmed in a dot-blot binding assay using both immo-
bilized C36L1 and iCDR peptides against recombinant murine 
CD74 protein (Figure  4B). These results suggest that C36L1 
could act as an antagonist of MIF, since its interaction occurs on 
critical binding sites used by MIF to interact with CD74.
To further investigate this, we performed a molecular docking 
study between C36L1 and CD74 protein. Docking calculations 
resulted in 122,000 different poses of which the worst 1% was 
discarded for presenting outliers’ energy values. The average 
energy of remaining structures was 60.8  kcal/mol, and more 
than 95% of them presented thermodynamically favorable 
binding energies (Figure S7C in Supplementary Material). The 
best solution occurred between C36L1 cluster 5 centroid and a 
CD74 structure with large opening (2.7 Å from reference) along 
normal mode 10, which shows an open–close motion. This 
pose presented −192.6  kcal/mol as free energy of binding and 
is depicted in Figure S7D in Supplementary Material. The key 
interaction elements observed in this complex were analyzed 
using BINANA algorithm. Hydrophobic contacts forming an 
extended pocket along the interface of all CD74 subunits were 
observed (Figure 4C). Stronger interactions were also observed: 
three critical hydrogen bonds, one salt bridge and one cation–π 
stacking interaction between CD74 and C36L1 peptide (Table 1; 
Figure 4D). Interestingly, C36L1 cluster 5 centroid appears in 30 
of top 50 best poses suggesting that this peptide conformation is 
likely to be privileged to bind CD74. Moreover, structures with 
large displacements along mode 10 of CD74 are more frequent; 
FigUre 4 | Binding prediction and molecular docking of C36L1 dynamic interactions to macrophage migration inhibitory factor (MIF) and its receptor CD74. (a) 
Binding probability of C36L1 peptide and irrelevant peptide (iCDR) to MIF and its receptor CD74 calculated using PepSite algorithm. Best ranked binding scores 
(n = 5) were included in the analysis for each group (***p < 0.001). (B) Dot-blot binding assay for C36L1 and iCDR peptides to mouse recombinant CD74. Bar 
graph represents mean of RLU in dot area quantified using ImageJ software from triplicates (n = 3), ***p < 0.001. (c) Hydrophobic pocket (orange) formed by CD74 
and C36L1 partners characterized by carbon–carbon interactions above a 4 Å distance cutoff. (D) Electrostatic interactions between CD74 and C36L1 peptide: 
hydrogen bonds formed between partners. Donor–acceptor distances are described; salt bridge formed involving K13; cation–π stacking between tyrosine residues 
of chain A of CD74 and C36L1. CD74 chains A, B, and C are colored in green, cyan, and magenta, respectively. C36L1 is colored in yellow. (e) Overlap of highest 
and lowest free energy results for C36L1 (cyan) in complex with CD74 (green). Left: Overlap of the lowest free energy 50 poses showing major concentration of 
C36L1 peptide at the CD74 N- and C-terminal interface. Lowest peptide free energy pose highlighted in red. Right: Overlap of the lowest free energy 50 poses, 
where C36L1 visits other regions of CD74, including the external region of the α-helices. Lowest peptide free energy highlighted in red.
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the worst ranked structures were less displaced. C36L1 interacts 
better with CD74 as it moves according to normal mode 10, 
whereas once CD74 returns to the relaxed conformation, the 
peptide-binding affinity decreases and the complex dissociates. 
Furthermore, the overlap of 50 best solutions showed a putative 
preferred binding region of C36L1 to the interface formed between 
N- and C-terminal portions of CD74 monomers. This binding 
site is confirmed by the observation of C36L1 main binding to 
CD74 α-helices, only in the worst solutions. In Figure 4E, blue 
arrows indicate spatial distribution of C36L1 (blue) over CD74 
altered structures (green), and the best and worst poses of C36L1 
are shown in red. A video representing the consequences of this 
dynamic interaction between C36L1 and CD74 tertiary structure 
is shown in Video S1 in Supplementary Material.
c36l1 Binds to cD74 on MOs and Dcs 
and Disrupts Downstream signaling
CD74 is a transmembrane protein mainly expressed in APCs and 
associated with the MHC II intracellular trafficking. CD74 is the 
TaBle 1 | Molecular docking main findings.
Parameters residues
Hydrogen bonds C36L1 CD74
ASN12 THR122-B
ASN12 TYR118-B
ASN12 GLU176-C
Salt bridges LYS13 GLU176-C
Cation–π stacking LYS13 TYR118-A
Scoring iAttract −192,575 (kcal/mol)
Hydrophobic contacts 81 (C–C)
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main receptor for MIF in MOs and DCs, and MIF binding to 
CD74 leads to immunosuppression of MOs, activation of myeloid-
derived suppressor cells, suppression of NK cells, and inhibition 
of T cell activation (29, 43, 47, 49–51). Thus, we evaluated whether 
C36L1 peptide (as predicted in the in silico approach) physiologi-
cally binds to CD74 receptor on MOs and DCs.
To address these interactions, primary bone marrow-derived 
MOs and DCs were incubated with biotinylated C36L1 probed 
with streptavidin-PE (red) and stained for CD74 (green). We 
observed that C36L1 binds to CD74 in both MOs and DCs 
(Figure  5A). CD74 can be expressed intracellularly and at the 
plasma membrane. Using confocal microscopy, we observed 
that C36L1 co-localizes with CD74 both intracellularly and at 
the cell membrane (Figure  5B). MIF interaction with CD74 
receptor activates different cell signaling pathways, including the 
PI3K/AKT and the MAPK signaling pathways (47, 49, 52). In 
agreement with this, we observed that recombinant MIF induces 
the phosphorylation of AKT (S473) and ERK (Thr202/Tyr204) 
in both primary MOs and DCs (Figure  5C). However, pre-
incubation of MOs and DCs with C36L1 inhibited MIF-induced 
AKT and ERK downstream signaling on MOs and DCs. These 
findings show that C36L1 binds to CD74 on MOs and DCs and 
disrupts MIF–CD74 signaling on these cells.
c36l1 inhibits MiF-induced suppression 
of MOs and Dcs and restores Their 
immunogenic and antitumorigenic 
Functions
To further understand the mechanism of action of C36L1 on 
MOs, we evaluated the immunosuppressive and tumor support-
ing functions of MOs exposed to MIF in the presence or absence 
of C36L1. MOs exposed to MIF supported the proliferation of 
melanoma cells (similar to what we observed when we exposed 
MOs to TCMs in Figure 2). C36L1 treatment abolished this MIF-
induced pro-tumorigenic function of MOs (Figure 6A). C36L1 
also significantly decreased the expression of the immunosup-
pressive factors TGF-β, IL-10, IL-6, Arginase-1, and PD-L1 by 
MOs exposed to MIF (Figure 6B).
To understand the mechanism of action of C36L1 on DCs, we 
evaluated the expression levels of DC activation markers as well as 
DCs ability to activate cytotoxic T cells in the presence or absence 
of MIF and C36L1 (Figure 6C). Treatment of primary myeloid 
DCs with MIF significantly decreased the levels of the matura-
tion and co-stimulatory markers CD86, CD80 and MHC-II. 
Treatment with C36L1 peptide counteracted the immuno-
suppressive effect of MIF on DCs (Figure  6D). DCs ability to 
activate cytotoxic T  cell killing function was also significantly 
impaired by MIF but rescued by C36L1 treatment (Figures 6C,E; 
Figure S8 in Supplementary Material). All together, these results 
provide functional evidence that C36L1 restores DCs and MOs 
immunogenic and antitumorigenic functions by interfering with 
the MIF/CD74 immunosuppressive signaling axis.
DiscUssiOn
Cutaneous melanomas are common in the Western hemisphere 
causing the majority (75%) of deaths related to skin cancer 
(53). The incidence rate of melanoma increases faster than for 
any other cancer (52). At very-early stages, melanomas can be 
surgically removed, and the 5-year survival rate of melanoma 
is 98%. However, melanoma can metastasize to distant organs 
including lungs, liver, bones, and brain, and the 5-year survival 
rate of patients with metastatic melanoma drastically decreases to 
15–20% (1, 2). Treatment with ICI has significantly increased the 
5-year survival rate of melanoma patients (1, 54), but the number 
of non-responders is still high, with the lack of response being 
currently intensively investigated. Mutations of gene families of 
cytokines, chemokine levels, mesenchymal transition, E-cadherin, 
and other proteins expressed in tumors are being studied (55). 
Understanding and targeting the immunosuppressive tumor 
microenvironment to restore an antitumor immune response is 
an area of great interest (7, 29, 56, 57). Therefore, understand-
ing the mechanisms by which metastatic melanoma suppresses 
antitumor immunity could further contribute to the development 
of new combinatorial agents that restore the immune response 
against metastatic melanoma.
Synthetic peptides based on immunoglobulin-CDR sequences 
have shown promising antitumor properties, and some of these 
peptides display immune stimulatory functions (22, 24–26).
We previously found that the C36 VL CDR1 peptide (C36L1) 
displays dose-dependent antitumor activities in  vitro against 
B16F10 melanoma cells, exerting microtubule de-polymerization 
at low concentrations and cell death at high concentrations (24). 
Our in vivo studies show that the antitumor effect induced by the 
C36L1 peptide strictly depends on its original sequence since the 
shuffled peptide was unable to exert any antitumor effects in the 
metastatic melanoma setting, and acted in a similar way as the PBS 
vehicle control (24). We also observed that the antitumor activity 
of C36L1 is not a general property of Ig-CDRs, since other CDR 
sequences (i.e., CE48-H2) did not show such antitumor effects 
(25). Short peptides can interact with more than one ligand, with 
variable affinities under different conditions or microenviron-
ments. We have previously uncovered peptide sequences that 
exert different therapeutic activities against infection diseases 
and cancer (22, 26, 27).
In this study, we uncover the mechanism by which C36L1 
restores an effective immune response against metastatic mela-
noma in vivo. We found that C36L1 is able to decrease melanoma 
metastatic growth in wild-type mice but not in immunodeficient 
mice, suggesting that in  vivo, the antitumor effect of C36L1 
requires the immune system. Specifically, we found that C36L1 
FigUre 5 | C36L1 interacts with CD74 in both macrophages (MOs) and dendritic cells (DCs) and inhibits macrophage migration inhibitory factor (MIF)/CD74 
signaling. (a) Immunofluorescent staining of C36L1 (red), CD74 (green), and nuclei (blue) in primary MOs and DCs. CD74 interactions with C36L1 were quantified 
using automated analysis in ImageJ. Arrows indicate merged channels depicted in white. Four fields per slide were quantified. Scale bars: 50 µm. (B) Representative 
fluorescent confocal microscopy images showing colocalization of C36L1 peptide (red) and CD74 (green) in the intracellular and surface focal plane of both primary 
MOs (left) and DCs (right). Co-localized points were detected using ImageJ colocalization algorithm, depicted in white. Scale bars: 10 µm. (c) Immunoblotting 
analysis of phosphorylated AKT and ERK1/2 on primary MOs (10 and 20 min, respectively) and DCs (5 min) previously treated with C36L1 (200 µg/mL) or left 
untreated, and further treated with recombinant MIF (200 ng/mL).
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is able to repolarize M2-like immunosuppressive TAMs into 
immunogenic and antitumorigenic M1-like MOs. C36L1 
also promotes the activation and immunogenicity of DCs. 
C36L1-driven activation of the innate immune system leads 
to the inhibition of immunosuppressive Tregs, the activation 
of effector T cells and subsequently to the killing of metastatic 
melanoma cells. Mechanistically, we found that C36L1 binds to 
the MIF receptor CD74 on MOs and DCs, thereby inhibiting MIF 
FigUre 6 | Continued
FigUre 6 | C36L1 blocks macrophage migration inhibitory factor (MIF) induced immunosuppressive effect on macrophages (MOs) and dendritic cells (DCs). (a) 
Top: Schematics describing the workflow of the tumor cell proliferation assay. B16F10 metastatic melanoma cells are exposed to conditioned media from: untreated 
MOs, MOs exposed to MIF (200 ng/mL), or MOs exposed to C36L1 (200 µg/mL) + MIF (200 ng/mL). The number of live proliferating B16F10 cells was quantified by 
flow cytometry after 72 h. Bottom: Bar graph represents average of three independent experiments (n = 3), mean ± SEM. Data were analyzed using a two-tailed 
unpaired t-test (***p < 0.001). (B) C36L1 blocks MIF-induced immunosuppressive effect on primary MOs. mRNA levels of TGF-β (n.s. = 0.058), IL-10 (*p = 0.049, 
p = 0.042), Arg.1 (**p = 0.002, ***p < 0.001), PD-L1 (**p = 0.0049, ***p < 0.001), and IL-6 (**p = 0.0015, ***p < 0.001) from MOs exposed to recombinant MIF in 
the presence or absence of C36L1 peptide. Experiment was performed in triplicates (n = 3). Values represent mean ± SEM and were analyzed using a two-tailed 
unpaired t-test. (c) Schematics describing the different conditions in which DCs were cultured and then used to activate T cells. Primary DCs were incubated with 
MIF (200 ng/mL) in the presence or absence of C36L1 peptide and activation markers were quantified by flow cytometry. These DCs were further pulsed with a 
melanoma antigen peptide and incubated with syngeneic purified CD8+ T cells. Next, T cells were harvested and incubated with melanoma B16F10 cells at a ratio 
of 10/1 CD8+ T cells/B16F10 tumor cell. (D) Quantification of MHC-II (p = 0.01), CD80 (p < 0.001), and CD86 (p = 0.02) activation markers in DCs performed by 
flow cytometry. Bar graph represents mean ± SEM, from three independent experiments (n = 3). Data were analyzed using a two-tailed unpaired t-test. (e) Bar 
graph showing the quantification of dead B16F10 cells after incubation with CD8+ T cells. Best of three independent experiments is shown, mean ± SEM from 
biological triplicates, one-tailed unpaired t-test (*p = 0.032).
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immunosuppressive effect on these innate immune cells, and 
shifting the balance from an immunosuppressive tumor microen-
vironment into a pro-inflammatory immunogenic environment 
in which the antitumor immune response is reinvigorated.
Tumors, including melanomas, secrete factors that inhibit the 
immune system. Among these factors, MIF has been recently 
shown to have immunosuppressive activities, in many cancers, 
including glioblastoma, breast, pancreatic cancer, and melanoma 
(29, 30, 49, 58–60). Thus, MIF is an emerging attractive target 
for immunotherapy. In pancreatic cancer, MIF is an important 
downstream regulator of fibrosis that culminates in the recruit-
ment of TAMs favoring metastasis (21). In cutaneous mela-
noma, MIF is produced by melanoma cells to support growth 
and induce immunosuppression (29, 30, 42–44, 51). However, 
the role of MIF in metastatic melanoma remains unclear. In 
glioblastoma, MIF can also induce pro-inflammatory functions, 
including M1-like MO polarization (58, 61). Bevacizumab, a 
monoclonal antibody that targets VEGF may also interact and 
neutralize MIF in glioblastomas, inducing the polarization of 
MOs into the M2-like phenotype that contributes to therapy 
resistance (58). This dual and opposite effect of MIF on the 
immune response depends on the cytokine milieu in the tumor 
microenvironment and on the levels of MIF. In fact, very low 
or high concentrations of MIF are thought to suppress the 
immune response, while intermediate doses rather promote 
pro-inflammatory and antitumor effects (58).
Different drugs targeting MIF and its main receptor CD74 
are in clinical development in many diseases, including cancer 
(31,  32, 48, 62–65). The MIF inhibitor 4-iPP is so far the only 
immunomodulatory agent described to be effective in melanoma 
and has shown promising results in subcutaneous melanoma, 
associated with an increase in monocyte pro-inflammatory 
functions (30). The effect of blocking MIF–CD74 signaling in 
metastatic melanoma has not yet been investigated. Targeting 
CD74 seems to be a promising anticancer therapeutic strategy to 
disrupt MIF-induced suppressive signaling effect on monocytes 
(31, 49, 65). The most well-characterized CD74 inhibitor is 
Milatuzumab, a monoclonal antibody approved for the treatment 
of chronic lymphocytic leukemia with acceptable side effects 
in humans including leukopenia, rash, nausea, and vomiting 
at low grade (65). In the field of drug discovery, peptide-based 
approaches emerge with intrinsic advantages, compared with 
antibodies including their small size, lack of immunogenicity, 
high affinity, specificity to different targets, low toxicity, good 
tissue penetration, and biocompatibility (22, 25, 26). Peptides 
can exert immunomodulatory functions and have been shown 
to neutralize immune checkpoint receptors in cancer (66–68). 
Indeed, linear peptides such as CDR peptides are flexible and 
likely to bind to different biologically relevant targets (41). Ig-CDR 
peptides, like C36L1, are mostly non-toxic in normal tissues and 
untransformed cell lines and are short living in the plasma due to 
proteolysis and renal filtration. However, since they can promptly 
interact with immune cells such as DCs and MOs, they could 
modulate the immune response in advanced stage melanomas.
In this study, we found that C36L1 interaction with the CD74 
receptor expressed on MOs and DCs is sufficient to inhibit 
MIF–CD74 signaling and to restore MOs and DCs antitumo-
rigenic functions (Figure 7). Our in silico studies show that the 
flexibility of this linear peptide allows its transient interaction 
with the CD74 receptor, disturbing its MD in the cell membrane. 
C36L1–CD74 interaction seems to be crucial to disrupt CD74 
interaction with MIF in both MOs and DCs. The cell inter-
nalization of CD74 conjugates is a well-known pharmacological 
characteristic of CD74 (50, 65), which has been recently explored 
as a drug-carrier strategy for the treatment of lymphomas and 
B  cell malignancies (65). CD74 internalization independent of 
MIF binding could impair the activation of downstream signaling 
(31, 69). In this respect, we found that C36L1 binds to CD74 at 
the cell membrane as well as in the intracellular space of MOs and 
DCs. This suggests that C36L1 binding to CD74 may promote 
its cytosolic internalization making it unavailable for binding to 
MIF. MIF binding to CD74 activates the PI3K/AKT and MAPK 
signaling pathways, and both these pathways have been related 
to monocyte immunosuppression, and MO M2-like polarization 
(45, 47, 49, 52). In agreement with these studies, we found that 
C36L1 inhibits MIF-induced AKT and ERK1/2 phosphorylation 
in both primary MOs and DCs and restores their antitumorigenic 
and immunogenic functions (Figure 7).
In conclusion, our findings suggest that MIF is highly secreted 
in metastatic melanoma and is an important immunosuppressor 
of MOs and DCs. Blocking MIF signaling through CD74 on MOs 
and DCs, using the C36L1 Ig-CDR-based peptide, restores the 
pro-inflammatory functions of MOs and DCs thereby harnessing 
the immune response against metastatic melanoma. This study 
FigUre 7 | Scheme of the mechanism of action of the C36L1 peptide in macrophages (MOs) and dendritic cells (DCs). C36L1 binds to receptor of macrophage 
migration inhibitory factor (MIF) CD74, thereby blocking its immunosuppressive effect on MOs and DCs (a), restoring their antitumorigenic functions and their 
capacity to activate and support an effective immune response against metastatic melanoma (B).
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provides a rationale for further evaluation of CDR-based peptides 
as therapeutic agents to restore the ability of MOs and DCs to 
start and shape an effective anticancer immune response.
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